Skip to main content

 Scientific publications

Thromboembolism and Immune Checkpoint Blockade in Cancer Patients: An Old Foe for New Research.

Authors : Langouo Fontsa M, Aiello MM, Migliori E, Scartozzi M, Lambertini M, Willard-Gallo K, Solinas C
Year : 2022
Journal : Target Oncol
Volume : 17
Pages : 497-505

Biomarkers and immunotherapy: where are we?

Authors : Langouo Fontsa M, Padonou F, Willard-Gallo K
Year : 2022
Journal : Curr Opin Oncol
Volume : 34
Pages : 579-586

A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma.

Authors : Gourari K, Catherine J, Garaud S, Kerger J, Lepida A, Georgala A, Lebrun F, Gomez Galdon M, Gil T, Willard-Gallo K, Langouo Fontsa M
Year : 2022
Journal : Diagnostics (Basel)
Volume : 12

The impact of tumor cell metabolism on T cell-mediated immune responses and immuno-metabolic biomarkers in cancer.

Authors : Noël G, Langouo Fontsa M, Willard-Gallo K
Year : 2018
Journal : Semin Cancer Biol
Volume : 52
Pages : 66-74

An atypical presentation of bronchial adenocarcinoma.

Authors : Langouo Fontsa M, CsToth I, Berghmans T, Feoli F, Meert AP
Year : 2013
Journal : Rev Med Brux
Volume : 34(3)
Pages : 181-3

Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles.

Authors : Aftimos P, Wiedig M, Langouo Fontsa M, Awada A, Ghanem G, Journe F
Year : 2013
Journal : Int J Oncol
Volume : 43(3)
Pages : 919-26